Regeneron Pharmaceuticals (REGN) Free Cash Flow (2009 - 2026)

Regeneron Pharmaceuticals has reported Free Cash Flow for 18 years, with the latest figure at $572.8 million in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 38.1% year-over-year to $572.8 million in Q2 2026; TTM through Jun 2026 was $4.5 billion, a 4.3% increase from a year earlier, with the FY2025 full-year figure at $4.8 billion, up 12.44% from the prior year.
• Free Cash Flow was $572.8 million for Q2 2026 at Regeneron Pharmaceuticals, down from $848.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $2.0 billion in Q1 2022, with the low at $336.3 million in Q2 2024.
• Average Free Cash Flow over 5 years is $1.0 billion, with a median of $906.0 million recorded in 2024.
• The largest YoY upside for Free Cash Flow was 230.12% in 2022 against a maximum downside of 85.17% in 2022.
• Over 5 years, Free Cash Flow stood at $1.6 billion in 2022, then sank by 46.53% to $838.3 million in 2023, then surged by 98.91% to $1.7 billion in 2024, then slipped by 1.55% to $1.6 billion in 2025, then tumbled by 65.11% to $572.8 million in 2026.
• The last three Free Cash Flow figures came in at $572.8 million (Q2 2026), $848.3 million (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.